Massive Bio Completes SOC 2 Type 1 Certification
NEW YORK--(BUSINESS WIRE)--Massive Bio, Inc., a leader in precision medicine and artificial intelligence (AI) enabled patient-centric clinical trial enrollment, today announced it has successfully achieved Type 1 Service Organization Control (SOC 2 ®) compliance examination for its flagship digital health platforms. The audit was performed by Control Logics, who have “implemented risk management methodologies and performed security assessments at over 200 companies located in North America, Europe and Asia” (Source: https://control-logics.com/). As more healthcare companies trust cloud service providers, it is important to ensure security of healthcare data. By achieving Type 1 certification, an independent third party has validated the design of Massive Bio’s controls relevant to its information security practices, policies, procedures, and operations meet the rigorous SOC 2 standards for security, availability, processing integrity, confidentiality, and privacy.
Developed by the American Institute of Certified Public Accountants (AICPA), SOC 2 ® certification is widely recognized as a gold standard for data security and requires companies to establish and follow strict information security policies and procedures. The goal of the SOC 2 Type 1 audit was to ensure Massive Bio’s operational controls meet the stringent standards of “security, availability, processing integrity, confidentiality, and privacy of a system” (Source: https://control-logics.com/soc-2-report/). The services reviewed by Control Logics for the report included Massive Bio’s enterprise solutions: the Clinical Trial Matching System (CTMS), Virtual Tumor Board (VTB), Real-World Insights and Evidence (RWE).